CA
LENZ

CHI Advisors’s LENZ Therapeutics LENZ Stock Holding History

CHI Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$573K Hold
32,991
– – 0.23% 24
2023
Q2 		$600K Buy
+32,991
New +$659K 0.18% 23

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CHI Advisors's LENZ Position: Q3 2023 in Review

CHI Advisors held its LENZ Therapeutics (LENZ) position steady in Q3 2023 at 32,991 shares worth $573K. The position accounts for 0.23% of the portfolio, ranked #24.

CHI Advisors first reported a position in LENZ in Q2 2023 and has held it in 2 quarters since. The position peaked at $600K in Q2 2023. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

  • CHI Advisors held 32,991 shares of LENZ Therapeutics worth $573K as of Q3 2023.
  • CHI Advisors left its LENZ Therapeutics share count unchanged in Q3 2023.
  • LENZ Therapeutics made up 0.23% of CHI Advisors's portfolio in Q3 2023, its #24 holding.
  • CHI Advisors first reported a position in LENZ Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • CHI Advisors's LENZ Therapeutics position peaked at $600K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.